|
Name |
1-Iodohexadecane
|
Molecular Formula | C16H33I | |
IUPAC Name* |
1-iodohexadecane
|
|
SMILES |
CCCCCCCCCCCCCCCCI
|
|
InChI |
InChI=1S/C16H33I/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17/h2-16H2,1H3
|
|
InChIKey |
KMWHQYDMBYABKL-UHFFFAOYSA-N
|
|
Synonyms |
1-IODOHEXADECANE; 544-77-4; Cetyl iodide; Hexadecyl iodide; Hexadecane, 1-iodo-; Hexadecane, iodo-; 1-iodo-hexadecane; 40474-98-4; JO95X48M8O; 1-Iodo-Hexadecan; UNII-JO95X48M8O; Cetyljodid; n-Hexadecyl iodide; 1-iodanylhexadecane; EINECS 208-879-4; DSSTox_CID_29273; DSSTox_RID_83392; DSSTox_GSID_49317; SCHEMBL562180; CHEMBL1233571; DTXSID0049317; ZINC6845604; Tox21_202845; MFCD00001089; STL280435; AKOS006029121; NCGC00260391-01; CAS-544-77-4; CS-0179397; FT-0607962; I0408; 1-Iodohexadecane contains copper as stabilizer; D91141; A830208; 1-Iodohexadecane, contains copper as stabilizer, 95%; Q27281601
|
|
CAS | 544-77-4 | |
PubChem CID | 11007 | |
ChEMBL ID | CHEMBL1233571 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 352.34 | ALogp: | 9.6 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 14 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 17 | QED Weighted: | 0.182 |
Caco-2 Permeability: | -4.828 | MDCK Permeability: | 0.00000859 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.174 |
30% Bioavailability (F30%): | 0.989 |
Blood-Brain-Barrier Penetration (BBB): | 0.06 | Plasma Protein Binding (PPB): | 98.74% |
Volume Distribution (VD): | 3.441 | Fu: | 1.27% |
CYP1A2-inhibitor: | 0.254 | CYP1A2-substrate: | 0.193 |
CYP2C19-inhibitor: | 0.372 | CYP2C19-substrate: | 0.063 |
CYP2C9-inhibitor: | 0.088 | CYP2C9-substrate: | 0.942 |
CYP2D6-inhibitor: | 0.268 | CYP2D6-substrate: | 0.085 |
CYP3A4-inhibitor: | 0.188 | CYP3A4-substrate: | 0.049 |
Clearance (CL): | 3.996 | Half-life (T1/2): | 0.057 |
hERG Blockers: | 0.228 | Human Hepatotoxicity (H-HT): | 0.047 |
Drug-inuced Liver Injury (DILI): | 0.574 | AMES Toxicity: | 0.034 |
Rat Oral Acute Toxicity: | 0.076 | Maximum Recommended Daily Dose: | 0.03 |
Skin Sensitization: | 0.948 | Carcinogencity: | 0.07 |
Eye Corrosion: | 0.996 | Eye Irritation: | 0.964 |
Respiratory Toxicity: | 0.906 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000429 | 0.891 | D07ILQ | 0.627 | ||||
ENC001240 | 0.816 | D00AOJ | 0.611 | ||||
ENC000427 | 0.815 | D0Z5SM | 0.585 | ||||
ENC000082 | 0.815 | D00FGR | 0.550 | ||||
ENC000400 | 0.772 | D05ATI | 0.500 | ||||
ENC000283 | 0.772 | D0O1PH | 0.456 | ||||
ENC000486 | 0.772 | D00STJ | 0.370 | ||||
ENC000426 | 0.759 | D0P1RL | 0.364 | ||||
ENC000379 | 0.759 | D0T9TJ | 0.349 | ||||
ENC000488 | 0.746 | D05QNO | 0.347 |